Last Updated:
Create account to add to watchlist!

Brookline Capital Acquisition Corp. - BCAC

  • Commons



    BCAC Vol: 16.5K

  • Warrants



    BCACW Vol: 4.8K

  • Units



    BCACU Vol: 9.7K

Average: 0
Rating Count: 0
You Rated: Not rated

Please log in to rate.

SPAC Stats

Market Cap: 74.1M
Average Volume: 11.8K
52W Range: $9.11 - $11.07
Weekly %: +0.06%
Monthly %: +0.20%
Inst Owners: 33


Target: Searching
Days Since IPO: 363
Unit composition:
Each unit has an offering price of $10.00 and consists of one share of our common stock and one half of one redeemable warrant
Trust Size: 5000000.0M


Our officers, directors and director nominees are as follows: Name Age Position Dr. Samuel P. Wertheimer 60 Chief Executive Officer and Chairman Scott A Katzmann 64 President and Director Nominee Patrick A. Sturgeon 44 Chief Financial Officer James N. Hauslein 61 Director Nominee Elgar Peerschke 64 Director Nominee Tito A. Serafini, PhD 56 Director Nominee Dr. Samuel P. Wertheimer, our Chairman and Chief Executive Officer since inception, has been an investor in the healthcare and life sciences sectors, entrepreneur, and scientist. He joined Brookline Capital Markets in 2017 as Senior Scientific Advisor. His role is to identify opportunities, diligence, structure investments, and raise capital for banking clients. From 2012 to 2016, he served as co-founder of Poliwogg, Inc. a financial services firm bringing innovation to healthcare investing. While at Poliwogg, he helped develop the Poliwogg Medical Breakthrough Index that serves as the underlying index for the ALPS Medical Breakthrough ETF (SBIO). From 2000 to 2011, Dr. Wertheimer was a Private Equity Partner at OrbiMed Advisors, LLC, one of the world’s largest healthcare-dedicated investment firms. At OrbiMed, Dr. Wertheimer was involved in raising and investing four venture capital funds with more than $1.5 billion in committed capital. He previously served on the boards of multiple public and private companies, including Biodel (NASDAQ: BIOD); a developer of drug delivery technologies, from 2006 to 2009; ChemoCentryx (CCXI), a development stage biotechnology company, from 2001 to 2011; Corus Pharma (acquired by Gilead), a development stage biotechnology company from 2001 to 2006; InteKrin Therapeutics (acquired by Coherus), a development stage biotechnology company from 2007 to 2010; NeurAxon, a development stage biotechnology company, from 2007 to 2010; and Salmedix (acquired by Cephalon), a development stage biotechnology company, from 2004 to 2005. He helped bring to market several new drugs including Treanda®, Cayston®, and Orbactiv®. Dr. Wertheimer received his Doctor of Philosophy degree from New York University, his Master of Public Health, with Honors, from Yale University and his Bachelor of Arts from the Johns Hopkins University. We believe he is well-qualified to serve as a Director due to his extensive operational and investment experience in the life sciences industry. Scott A. Katzmann, our President since inception, who will be one of our Directors upon the effective date of the registration statement of which this prospectus forms part, is a co-founder of Brookline Capital Markets. At Brookline Capital Markets, Mr. Katzmann leads its Private Capital team. Prior to co-founding Brookline in 2016, Mr. Katzmann served as Senior Managing Director of Opus Point Partners, an investment firm dedicated to healthcare and life science investing, from 2011 to 2013. Mr. Katzmann was formerly a Managing Director at Paramount BioCapital from 1993 to 2011. Prior to Paramount, Mr. Katzmann held similar investment banking positions at First Boston and its successor, Credit Suisse First Boston. Mr. Katzmann received his B.A. in Economics from Tulane and his M.B.A. from the Wharton School at the University of Pennsylvania. We believe he is well-qualified to serve as a Director due to his extensive investment and capital management experience. Patrick A. Sturgeon, our Chief Financial Officer since inception, has nearly two decades of experience with M&A and equity capital market transactions in the healthcare and other sectors. He has served as a Managing Director at Brookline Capital Markets, since 2016. At Brookline, Mr. Sturgeon focuses on mergers and acquisitions, public financing, private capital raising, secondary offerings, and capital markets. On the public financing front, he focuses on SPAC transactions, primarily underwritten initial public offerings and initial business combinations. From 2013 to 2016, Mr. Sturgeon served as a Managing Director at Axiom Capital Management. He worked at Freeman & Co. from 2002 to 2011, where he focused on mergers and acquisitions in the financial services sector. Since July 2020 he has served as Chief Financial Officer and Secretary of Alpha Healthcare Acquisition Corp., a blank check company which has filed a registration statement in connection with its initial public offering. Mr. Sturgeon received his B.S. in Economics from the University of Massachusetts, Amherst and his M.B.A in Finance from New York University. 98 James N. Hauslein, who will be one of our Directors upon the effective date of the registration statement of which this prospectus forms part, has served as a Managing Director of Hauslein & Company, Inc., a private investment firm, since 1990. In 2015, Mr. Hauslein led the recapitalization/acquisition of Big Time Products LLC, or BTP, a leading supplier of workplace hand protection and related products into the consumer DYI/Pro retail channel (The Home Depot, Wal-Mart, ACE, True Value et. al.). The 2015 recapitalization was in partnership with BTP’s co-founders and three institutional investors. In 2018, BTP was sold to the Hillman Group (a portfolio company of CCMP). During the period that Mr. Hauslein was a shareholder of BTP, he served as Executive Chairman and then Chief Executive Officer. Under Mr. Hauslein’s leadership, BTP completed its first add-on acquisition in 2015 and its second add-on acquisition in 2016. Under Mr. Hauslein’s leadership, the company became a leader in the non-apparel ‘work gear’ product category. Mr. Hauslein was involved in the acquisition of a controlling interest in Sunglass Hut International in 1987 and subsequently led the buyout in 1991 and the initial public offering in 1993. Mr. Hauslein served as Executive Chairman of Sunglass Hut International from 1991 until 2001, and for part of his tenure was Chief Executive Officer of Sunglass Hut (1997 to 1998 and for several months in 2001). Under Mr. Hauslein’s leadership, Sunglass Hut grew in revenue from approximately $37 million in 1987 to approximately $680 million in 2000 prior to the sale to Luxottica Group SpA. At the time of the sale to the Luxottica Group, Sunglass Hut operated approximately 2,000 company-owned stores in North America, Europe, Asia and the Caribbean. While at Sunglass Hut, Mr. Hauslein presided over numerous add-on acquisitions in the United States and Australia as well as organic growth in North America, the Caribbean, and Europe and a joint venture in Singapore. Mr. Hauslein previously served on the Board of Directors of Atlas Acquisition Holdings Corp., Easterly Acquisition Corp., Freedom Acquisition Holdings Inc., GLG Partners, Inc. and Liberty Acquisition Holdings Corp. Mr. Hauslein served as Chairman and Chief Executive Officer of Atlas Acquisition Holdings Corp. from 2007 until 2010. Atlas Acquisition Holdings Corp. liquidated in 2010 and did not complete a business combination. Freedom Acquisition Holdings Inc. completed a business combination with GLG Partners, Inc. in 2007 and GLG Partners, Inc. was subsequently sold to the Mann Group in 2010. Liberty Acquisition Holdings Corp. completed a business combination with Promotora de Informaciones S.A. in 2010. Prior to completing a business combination with Sirius International Insurance Group, Mr. Hauslein resigned from the Board of Directors of Easterly Acquisition Corp. Mr. Hauslein is not currently an officer or director of any of these companies. From 2015 until 2018, Mr. Hauslein served on the board of NB Parent Company, the parent holding company for Big Time Products, LLC. Mr. Hauslein received his MBA from Cornell University’s Johnson Graduate School of Management, and his Bachelor of Science in Chemical Engineering from Cornell University. Mr. Hauslein is well-qualified to serve on our Board of Directors due to his operational experience, diversified board experience, his knowledge of private equity, and his prior special purpose acquisition company experience. Elgar Peerschke, who will be one of our Directors upon the effective date of the registration statement of which this prospectus forms part, is a C-level executive with multi-national experience in the US, Europe, and Latin America. Over the course of his career he has had extensive regional and global P&L responsibilities. He has been acting in the capacity of independent investor and advisor since 2017. From 2014 to 2017, he served as Senior Advisor to several C-suite executive officers at IQVIA, a human data science company. In these roles, Mr. Peerschke was responsible for driving the consultative sales organizations as well as large deals/sole providerships for QuintilesIMS, a global provider of technology solutions and contract research services to the healthcare industry. Prior to IQVIA, Mr. Peerschke spent over 20 years in consulting, focusing on serving clients in the healthcare industry, primarily pharma/biotech and related services companies with extensive in clinical development strategy/operations, market access and product launch as well as organization design, performance improvement, corporate M&A, diligence, growth opportunities and post-merger integration. He is a director of ARdVRk Technologies, a private virtual reality company in the healthcare and life sciences field. Over his 20 years in consulting, he held various leadership positions at Bain & Company, including as Managing Director — North American Healthcare Practice and Managing Director — Global Healthcare Practice, as well as McKinsey and Company prior to that. Mr. Peerschke holds an MBA from New York University in Finance and a BA from Rutgers University in Political Science. We believe he is well-qualified to serve as a Director due to his extensive investment, operational and consulting experience. Tito A. Serafini, PhD, who will be one of our Directors upon the effective date of the registration statement of which this prospectus forms part, is one of the three principal founders of Atreca, Inc. (Nasdaq: BCEL), a public, development-stage biotechnology company, where he serves as a member of the board of directors. Dr. Serafini was the Chief Executive Officer from Atreca’s inception in 2010 until 2018, and as part of his current operational role as 99 Chief Strategy Officer, Dr. Serafini is responsible directly for the non-clinical technical organization of the company. Before founding Atreca, he was Chief Scientific Officer of Nuon Therapeutics, a development-stage biotechnology company, from 2009 to 2011. Prior to his role at Nuon, Dr. Serafini was a co-founder of Renovis, Inc., where he served as an executive officer in multiple roles, including leading research and M&A functions. Prior to founding Renovis, Dr. Serafini was an award-winning faculty member in the Department of Molecular and Cell Biology at the University of California, Berkeley, where he established the university’s Functional Genomics Laboratory. Dr. Serafini received a BS in biochemistry from Case Western Reserve and a PhD in biochemistry from Stanford University (advised by Dr. James Rothman), and he performed postdoctoral research at the University of California, San Francisco, in the laboratory of Dr. Marc Tessier-Lavigne. We believe he is well-qualified to serve as a Director due to his extensive scientific and operational experience. Prior Blank Check Experience Mr. Hauslein has served as a founder, Chief Executive Officer or as a director of four blank check companies formed for the purpose of effecting a business combination, raising an aggregate of almost $2 billion in their initial public offerings. None of these companies changed its intentions from what each disclosed in its respective initial public offering prospectus. Mr. Hauslein is not currently an officer or director of any of these companies. Freedom Acquisition Holdings, Inc. Freedom Acquisition Holdings, Inc. raised $528 million in January 2007 and completed a $3.4 billion business combination with hedge fund GLG Partners later that year. Mr. Hauslein served as a Director on the Board of Directors of Freedom Acquisition Holdings and of the combined entity. Liberty Acquisition Holdings Corp. Mr. Hauslein served as a Director of Liberty Acquisition Holdings Corporation, which raised $1.035 billion in December 2007 and completed its $8.0 billion business combination with Promotora de Informaciones, S.A., a large Spanish and Portuguese-language media group, in November 2010. Atlas Acquisition Holdings Corp. Mr. Hauslein served as Co-founder, Chairman and Chief Executive Officer of Atlas Acquisition Holdings Corporation, a consumer-focused blank check company which raised $200 million when it went public in 2008. Atlas did not complete its business combination with Select Staffing Inc. and distributed the funds held in trust to its stockholders. Easterly Acquisition Corp. Mr. Hauslein served as a Director on Easterly Acquisition Corp, a blank check company that went public in July 2015, raising $200 million. Prior to completing its $2.196 billion business combination with Sirius International Insurance Group in 2018, Mr. Hauslein resigned as a Director. Number and Terms of Office of Officers and Directors We will have five directors upon completion of this offering. Our board of directors will be divided into two classes with only one class of directors being elected in each year and each class (except for those directors appointed prior to our first annual meeting of stockholders) serving a two-year term. In accordance with NASDAQ corporate governance requirements, we are not required to hold an annual meeting until one year after our first fiscal year end following our listing on NASDAQ. The term of office of the first class of directors, consisting of Messrs. Peerschke and Hauslein, will expire at our first annual meeting of stockholders. The term of office of the second class of directors, consisting of Messrs. Serafini, Katzmann and Wertheimer, will expire at the second annual meeting of stockholders. Our officers are appointed by the board of directors and serve at the discretion of the board of directors, rather than for specific terms of office. Our board of directors is authorized to appoint persons to the offices set forth in our bylaws as it deems appropriate. Our bylaws provide that our officers may consist of a Chairman of the Board, a Chief Executive Officer, Chief Financial Officer, President, Vice Presidents, Secretary, Treasurer, Assistant Secretaries and such other offices as may be determined by the board of directors. 100 Director Independence NASDAQ listing standards require that a majority of our board of directors be independent. An “independent director” is defined generally as a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out the responsibilities of a director. Our board of directors has determined that Messrs. Hauslein, Peerschke and Serafini are “independent directors” as defined in the NASDAQ listing standards and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present. Officer and Director Compensation None of our officers has received any cash compensation for services rendered to us. Commencing on the date of this prospectus, we have agreed to pay an affiliate of our sponsor a total of $10,000 per month for office space, utilities and secretarial and administrative support. Upon completion of our initial business combination or our liquidation, we will cease paying these monthly fees. Other than as set forth elsewhere in this prospectus, no compensation of any kind, including any finder’s fee, reimbursement, consulting fee or monies in respect of any payment of a loan, will be paid by us to our sponsor, officers, directors or any affiliate of our sponsor, officers or directors, prior to, or in connection with any services rendered in order to effectuate, the consummation of our initial business combination (regardless of the type of transaction that it is) except that we may pay Brookline or its affiliates, partners or employees, a fee for financial advisory services rendered in connection with our identification, negotiation and consummation of our initial business combination; the amount of any fee we pay to Brookline or its affiliates, partners or employees, will be based upon the prevailing market for similar services for such transactions at such time, and will be subject to the review of our audit committee pursuant to the audit committee’s policies and procedures relating to transactions that may present conflicts of interest. Our officers and directors will be reimbursed for any out-of-pocket expenses incurred in connection with activities on our behalf such as identifying potential target businesses and performing due diligence on suitable business combinations. Our audit committee will review on a quarterly basis all payments that were made to our sponsor, officers, directors, advisors or our or their affiliates. Any such payments prior to an initial business combination will be made using funds held outside the trust account. Other than quarterly audit committee review of such payments, we do not expect to have any additional controls in place governing our reimbursement payments to our directors and executive officers for their out-of-pocket expenses incurred in connection with identifying and consummating an initial business combination. After the completion of our initial business combination, directors or members of our management team who remain with us may be paid consulting or management fees from the combined company. All of these fees will be fully disclosed to stockholders, to the extent then known, in the tender offer materials or proxy solicitation materials furnished to our stockholders in connection with a proposed initial business combination. We have not established any limit on the amount of such fees that may be paid by the combined company to our directors or members of management. It is unlikely the amount of such compensation will be known at the time of the proposed initial business combination, because the directors of the post-combination business will be responsible for determining officer and director compensation. Any compensation to be paid to our officers will be determined, or recommended to the board of directors for determination, either by a compensation committee constituted solely by independent directors or by a majority of the independent directors on our board of directors. We do not intend to take any action to ensure that members of our management team maintain their positions with us after the consummation of our initial business combination, although it is possible that some or all of our officers and directors may negotiate employment or consulting arrangements to remain with us after our initial business combination. The existence or terms of any such employment or consulting arrangements to retain their positions with us may influence our management’s motivation in identifying or selecting a target business but we do not believe that the ability of our management to remain with us after the consummation of our initial business combination will be a determining factor in our decision to proceed with any potential business combination. We are not party to any agreements with our officers and directors that provide for benefits upon termination of employment. 101 Committees of the Board of Directors Our board of directors will have two standing committees: an audit committee and a compensation committee. Subject to phase-in rules and a limited exception, NASDAQ rules and Rule 10A-3 of the

Holder Stats

1 0
% of Shares Held by All Insider 0.00%
% of Shares Held by Institutions 36.34%
% of Float Held by Institutions 36.34%
Number of Institutions Holding Shares 33

Mutual Fund Holders

Holder Shares Date Reported Value % Out
RiverNorth Specialty Finance Corporation 37588 2021-09-29 374000 0.51
RiverNorth Opportunities Fd 17396 2021-10-30 173441 0.22999999999999998
Fidelity NASDAQ Composite Index Fund 1762 2021-10-30 17567 0.02
Saba Capital Income & Opportunities Fd 806 2021-10-30 8035 0.01

Institutional Holders

Reporting Date Hedge Fund Shares Held Market Value % of Portfolio Quarterly Change in Shares Ownership in Company
2021-11-16 Schonfeld Strategic Advisors LLC 15,568 $160,000 0.0% 0 0.735%
2021-11-16 Jane Street Group LLC 75,653 $750,000 0.0% +1.8% 3.570%
2021-11-16 Millennium Management LLC 47,889 $480,000 0.0% +35.3% 2.260%
2021-11-15 Berkley W R Corp 74,426 $740,000 0.0% +35.3% 3.512%
2021-11-12 Wolverine Asset Management LLC 31,406 $310,000 0.0% -15.1% 1.482%
2021-11-09 Basso Capital Management L.P. 281,120 $2,800,000 0.3% +111.3% 13.260%
2021-10-28 Mizuho Securities USA LLC 12,674 $130,000 0.0% 0 0.598%
2021-08-17 Millennium Management LLC 35,389 $350,000 0.0% 0 1.670%
2021-08-13 GABELLI & Co INVESTMENT ADVISERS INC. 11,100 $110,000 0.0% 0 0.524%
2021-08-13 Basso Capital Management L.P. 133,014 $1,320,000 0.2% +227.6% 6.277%
2021-08-13 Gabelli Funds LLC 10,229 $100,000 0.0% 0 0.483%
2021-08-12 Kepos Capital LP 45,826 $460,000 0.0% 0 2.163%
2021-08-11 Panagora Asset Management Inc. 3,386 $34,000 0.0% 0 0.160%
2021-08-11 CVI Holdings LLC 100,000 $990,000 0.1% 0 4.719%
2021-08-03 Landscape Capital Management L.L.C. 20,987 $210,000 0.0% 0 0.990%
2021-05-18 Fir Tree Capital Management LP 300,000 $2,950,000 0.1% 0 14.158%
2021-05-18 Berkley W R Corp 55,001 $540,000 0.1% 0 2.596%
2021-05-18 Rivernorth Capital Management LLC 99,998 $980,000 0.1% 0 4.719%
2021-05-18 Karpus Management Inc. 130,242 $1,280,000 0.0% 0 6.146%
2021-05-18 Tudor Investment Corp Et Al 200,000 $1,970,000 0.0% 0 9.438%
2021-05-18 Alyeska Investment Group L.P. 17,000 $170,000 0.0% 0 0.802%
2021-05-18 Radcliffe Capital Management L.P. 131,765 $1,300,000 0.1% 0 6.218%
2021-05-18 Jane Street Group LLC 57,970 $570,000 0.0% 0 2.736%
2021-05-17 Polar Asset Management Partners Inc. 75,652 $740,000 0.0% 0 3.570%
2021-05-14 Periscope Capital Inc. 417,400 $4,099,999 0.2% 0 19.698%
2021-05-14 Bulldog Investors LLP 37,664 $370,000 0.1% 0 1.777%
2021-05-13 Wolverine Asset Management LLC 29,327 $290,000 0.0% 0 1.384%
2021-05-13 Knott David M 4,000 $39,000 0.0% 0 0.189%
2021-05-12 UBS Group AG 2,683 $26,000 0.0% 0 0.127%
2021-05-10 Basso Capital Management L.P. 40,602 $400,000 0.1% 0 1.916%

SEC Filings

Form Type Form Description Filing Date Document Link
8-K 8-K 2021-12-15
10-Q 10-Q 2021-12-09
8-K/A 8-K/A 2021-11-24
8-K 8-K 2021-11-24
NT 10-Q NT 10-Q 2021-11-15
10-Q 10-Q 2021-08-16
10-Q 10-Q 2021-06-07
8-K 8-K 2021-06-04
NT 10-Q NT 10-Q 2021-05-17
SC 13G/A 2021-03-10
8-K CURRENT REPORT 2021-02-18
SC 13D SCHEDULE 13D 2021-02-12
SC 13G 2021-02-10
8-K CURRENT REPORT 2021-02-08
4 2021-02-04
8-K CURRENT REPORT 2021-02-02
424B4 2021-01-29
EFFECT 2021-01-28
3 2021-01-28
3 2021-01-28
3 2021-01-28
8-A12B/A AMENDMENT NO. 1 TO FORM 8-A12B 2021-01-27
CERT 2021-01-25
S-1/A AMENDMENT NO. 3 TO FORM S-1 2021-01-07
S-1/A AMENDMENT NO. 1 TO FORM S-1 2020-08-24
DRS 2020-07-17